Medical Treatment Predicts Mortality After Hip Fracture by Juliebø, Vibeke et al.
Journal of Gerontology: MEDICAL SCIENCES  © The Author 2009. Published by Oxford University Press on behalf of The Gerontological Society of America. This is an Open Access article
Cite journal as: J Gerontol A Biol Sci Med Sci  distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5),
2010 Vol. 65A, No. 4, 442–449  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
doi:10.1093/gerona/glp199  Advance Access published on December 18, 2009 
 
442
A
pproximAtely 1.6 million hip fractures occur every 
year worldwide, and the incidence of hip fracture is in-
creasing with increasing longevity (1–5). Hip fracture has 
been associated with increased morbidity and mortality; pre-
vious studies have reported that the risk of mortality is highest 
the first 6 months after the fracture, and after 1 year, the risk is 
reported to be in the range of 20%–25% (6–9). Despite im-
proved surgical treatment, the mortality rates after hip fracture 
have remained high and stable over the past 50 years (3).
patients admitted with a hip fracture are often frail and in 
need of medical evaluation and management. Knowledge of 
medical risk factors associated with mortality is necessary 
for the development of appropriate management strategies. 
Higher age and male sex are the most common risk factors 
identified across several studies (10–12). other risk factors 
like time to surgery are inconsistently reported, and poten-
tially important risk factors like use of medications, body 
mass index (Bmi), and degree of cognitive impairment have 
been omitted in most studies (10,11,13,14). one study re-
ported that patients with multiple comorbidities and clini-
cally  diagnosed  postoperative  complications,  like  chest 
infections and congestive heart failure (CHF), were at a 
higher risk of mortality (14). to our knowledge, no previous 
study has looked into medications as potential risk factors 
for mortality in this patient group.
Accordingly, the aims of this study were to identify com-
mon causes of death and to investigate whether medications 
and prefracture medical conditions predicted mortality after 
hip fracture when adjusting for potential confounders.
Methods
Study Design
this is a prospective observational study of patients ad-
mitted to oslo University Hospital, Ullevaal, and Diakon-
hjemmet  Hospital  in  oslo,  Norway,  from  the  5th  of 
September 2005 through 31st of December 2006. the pa-
tients were included on admission. information on time and 
cause of death, in the period from the 5th of September 
2005 through 31st of December 2007, was obtained from 
the Norwegian Cause of Death register.
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Participants
patients were eligible for inclusion if they were acutely 
admitted for a hip fracture, 65 years of age or older, and able 
to speak Norwegian; had no severe aphasia, head injury, or 
terminal illness; were admitted for at least 24 hours; and 
had not been included in the same study for a previous hip 
fracture. A research team, two researchers and three study 
nurses, performed daily reviews of the patient registries of 
the orthopedic departments at oslo University Hospital, Ul-
levaal, and Diakonhjemmet Hospital in oslo to identify pa-
tients admitted with hip fracture (femoral neck fracture and 
intertrochanteric or subtrochanteric fracture). the patient 
registry was validated against the surgery records as well as 
the discharge diagnoses.
Cross-sectional data of the same cohort have previously 
been published (15). of 575 consecutive patients admitted 
during the study period, 368 were initially enrolled, whereof 
4 withdrew after enrollment. Failure to meet the eligibility 
criteria was the most common reason for not being enrolled 
(n = 111); including length of stay <24 hours (n = 85), too 
ill for approach or death (n = 13), did not speak Norwegian 
(n = 3), aphasia (n = 3), included earlier (n = 7) (15). in all, 
364 patients were included; of whom, 255 signed their own 
consent form and 109 were enrolled based on presumed 
consent in combination with assent from next of kin. mean 
age  was  83.4  years;  276  (75.8%)  patients  were  women. 
there were no statistically significant differences between 
patients enrolled (n = 364) and patients not enrolled (n = 
211) with respect to the distribution of age (p = .63) or gen-
der (p = .90). the 85 patients who were excluded due to 
length of stay <24 hours were more likely to be nursing 
home residents compared with those enrolled.
Measurements and Procedures
potential risk factors for mortality were selected based on 
literature review and expert opinion. risk factors were col-
lected from medical records, anesthesiology records, infor-
mation from the orthopedic unit staff, patient interview and 
observation, proxy interview and questionnaires, and sup-
plemented  by  information  from  nursing  home  staff  and 
home helpers when relevant.
members of the research team performed all cognitive 
and  functional  assessments. the  team  followed  standard 
procedures, had extensive training, and was not involved in 
the care of the enrolled patients. All patients were assessed 
daily (weekdays), through the fifth postoperative day or un-
til discharge, for complications and other risk factors. pa-
tients admitted on weekends were assessed by the regular 
staff and included retrospectively within 48 hours of admis-
sion. Biomedical factors included diagnoses on admission, 
medications on admission, the American Society of Anes-
thesiologists’ (ASA) score (16), type of fracture, Bmi, and 
complications. ASA score was collected from the anesthesi-
ology records, and type of fracture and operation were col-
lected from the surgery records. Diagnoses and medications 
on admission were collected from previous medical records, 
information from patients and their general practitioner, and 
supplemented by information from relatives, nursing home 
staff, and home care staff. the body weight was measured 
using a chair scale on the first or second day postoperatively, 
and the height was estimated from length of the patients in 
supine position. medications were classified according to 
the Anatomical therapeutic Chemical classification system. 
Complications,  diagnosed  clinically  by  the  regular  staff, 
were broadly defined as any event occurring within 5 days 
of surgery requiring treatment measures that are not rou-
tinely applied postoperatively in hip fracture patients.
process of care factors included delay to surgery and time 
in the operation theater. Clinical findings on admission and 
postoperatively were collected from medical records and in-
cluded lowest mean arterial pressure (mAp = (systolic blood 
pressure + (2 × diastolic blood pressure))/3), heart rate, tem-
perature, and cardiac rhythm as assessed by a standard 12-
lead  electrocardiogram.  the  regular  staff  performed  the 
electrocardiograms on admission, and the cardiac rhythm 
was retrospectively evaluated by one of the researchers. if 
clinical  findings  were  missing  in  the  hospital  records,  a 
member of the research team performed the measurements. 
Surgical treatment variables, including type of surgery per-
formed, type of anesthesia, and lowest mAp during surgery, 
were collected from the hospital records. laboratory studies 
were measured according to standard hospital procedure.
prefracture cognitive status was estimated by the infor-
mant  Questionnaire  on  Cognitive  Decline  in  the  elderly 
Short Form (iQCoDe-SF) (17,18), a 16-item instrument 
developed to acquire proxy information on the patient’s per-
formance in daily tasks that require memory. iQCoDe-SF 
was completed by a caregiver with regular face-to-face con-
tact with the patient at least once in every 14 days. prefracture 
functioning in activities of daily living (ADl) was determined 
by the Barthel index scored by a close caregiver seeing the 
patient at least once in every 14 days. A score of 19 or 20 out 
of 20 was considered indicative of functional independence. 
For the iQCoDe-SF as well as the Barthel index, we asked 
the informant to describe the patient’s condition 14 days 
prior to the fracture in order to ascertain the patient’s func-
tion as far as possible in a stable clinical phase and not bi-
ased by a potential acute or subacute condition leading to 
the injury. of 364 patients, 292 had a close caregiver willing 
to complete the iQCoDe-SF and Barthel index. We did not 
replace missing data, and the 72 patients without proxy in-
formation were hence excluded in the Cox proportional haz-
ards model. there were no statistically significant differences 
between patients with missing data (n = 72) and patients not 
with missing data (n = 292) with respect to the distribution 
of age (p = .51), gender (p = .43), ASA score (p = .42), place 
of residence (p = .26), the use of diuretics (p = .27), the use 
of statins (p = .83), Bmi < 20 (p = .37), or heart rate > 100 
(p = .75).JULIEBø ET AL. 444
Outcomes
the primary outcome was mortality, and the secondary 
outcome was cause of death. Date and cause of mortality 
was obtained from the Cause of Death register. median 
follow-up was 21.1 months in patients alive at the end of 
study (range 12.2–27.8 months).
Bias Reduction: Stratification by Propensity Score 
Quintiles
in view of the fact that this is an observational study 
and that patients are not randomly assigned to prescription 
of drugs, there are differences in observed covariates be-
tween the treatment and the control groups. in order to 
balance the covariates and minimize the risk of biased es-
timates, we stratified for the patients’ probability or pro-
pensity to receive diuretics in the final survival analysis. 
the propensity score (pS) for an individual is defined as 
the conditional probability of being treated given the indi-
vidual’s covariates (19). We estimated the pS for diuretic 
therapy for each patient by multiple logistic regression 
analysis in which the receipt of diuretics was modeled us-
ing all baseline patient characteristics in table 1. We also 
estimated the pS for statin therapy using the same base-
line characteristics.
Statistical Analyses
Survival was estimated by Kaplan–meier plots and com-
pared between groups by the log rank test. Cox proportional 
hazards model was used to assess the simultaneous effect of 
variables identified as risk factors (p < .05 in separate log 
rank tests), stratifying for pS quintiles for diuretic therapy. 
the assumption of proportionality was checked by visual 
inspection of log hazard plots.
if two variables demonstrated a correlation higher than 
0.6, the one with weakest association with the outcome 
was omitted. Variable selection was done both by forward 
selection and by backward elimination, and the different 
models were compared with respect to p values of the dif-
ferent variables as well as the difference in log likelihood 
between models. For multilevel explanatory variables, an 
approximately linear relationship between the score lev-
els and effect was assessed, and adjacent categories were 
collapsed as appropriate. Variables significantly associ-
ated with mortality in Cox regression survival analysis 
were finally checked for interactions (one at a time). mul-
ticollinearity was checked by exploring the variance in-
flation  factor.  Any  relationship  between  potential  risk 
factors  and  use  of  diuretics  was  analyzed  by  the  chi-
square test.
to assess the robustness of our findings regarding the ef-
fects of diuretics and statins on mortality, we conducted 
sensitivity analyses adjusting for the probability of using 
diuretics and statins, respectively, using both the pS raw 
score and the stratification for pS quintiles in the model. 
Statistical calculations were performed using SpSS for win-
dows, version 15 (SpSS, inc., Chicago, il).
Ethical Considerations
the study was undertaken in accordance with the Decla-
ration of Helsinki and was approved by the regional Com-
mittee for ethics in medical research, the Data inspectorate, 
as well as the Directorate of Health.
table 1.  Characteristics of the patients
n = 364
Background characteristics
  Age at fracture (y), mean (SD) 83.4 (6.8)
  male sex, n (%) 88 (24.2)
  Female sex, n (%) 276 (75.8)
  living in nursing home, n (%) 56 (15.4)
  iQCoDe*, mean (SD) 3.74 (0.79)†
  Cognitively impaired, iQCoDe > 3.6, n (%) 141 (42.6)
  Barthel index ≤ 18/20, n (%) 140 (47.9)‡
  Body mass index ≤ 20, n (%) 89 (27.1)§
  ASA‖ group iii, iV, or V, n (%) 182 (50.0)
  History of
    Hypertension, n (%) 121 (33.2)
    Congestive heart failure, n (%) 39 (10.7)
    Coronary heart disease (previous myocardial infarction,  
      angina pectoris, or other ischemic heart disease), n (%)
70 (19.2)
    previous stroke, n (%) 64 (17.6)
    obstructive pulmonary disease, n (%) 30 (8.2)
  Use of
    Acetylsalicylic acid, n (%) 116 (31.9)
    Beta-blockers, n (%) 84 (23.1)
    Diuretics, n (%) 109 (29.9)
      loop diuretics 86
      others 23
    Statins, n (%) 52 (14.3)
      Simvastatin 37
      Atorvastatin 11
      others 4
  Angiotensin-converting enzyme inhibitor or angiotensin  
        receptor antagonist, n (%)
91 (25)
preoperative characteristics on admission
  Atrial fibrillation on admission, n (%) 48 (14.0)¶
  mean arterial pressure (mmHg), mean (SD) 108.2 (17.1)
  Heart rate > 100 beats per min, n (%) 41 (11.3)
  Body temperature >37.5°C, n (%) 139 (38.2)
  time (h) from admission to surgery, mean (SD) 23.4 (23.7)
perioperative and postoperative characteristics
  time (h) in operation theater, mean (SD) 2.1 (1.0)
  type of operation, n (%)
    Hemiarthroplasty 131 (36.1)
    Arthroplasty 4 (1.1)
    osteosynthesis 228 (62.8)
  type of anesthesia, n (%)
    General 20 (5.5)
    Spinal 337 (92.6)
    others 7 (1.9)
  received blood transfusion during the stay, n (%) 127/362 (64.9)
Notes: *the informant Questionnaire on Cognitive Decline in the elderly 
Short Form (17,18).
† n = 292.
‡ n = 291.
§ n = 329.
‖ American Society of Anesthesiologists (16).
¶ n = 342. RISK FACTORS OF MORTALITY AFTER HIP FRACTURE 445
Results
the univariate analyses were conducted with a total of 
364 patients, and characteristics of the enrolled patients are 
shown in table 1. the Cox model was conducted with a 
total of 292 patients. ten of 364 patients (2.7%) died during 
the first month of follow-up, 16.2% (n = 59) had died at 6 
months, 22.5% (n = 82) had died at 1 year, and 28.6% (n = 
99) had died at the end of follow-up.
of 36 potential risk factors with prevalence more than 
5%, 21 variables were significantly associated with mortal-
ity  in  univariate  analysis.  the  unadjusted  hazard  ratios 
(Hrs) of the variables are shown in table 2. Seven statisti-
cally significant factors increasing the risk of death after hip 
fracture were identified using the Cox model: use of diuret-
ics, history of coronary heart disease (CHD) (previous myo-
cardial infarction, angina pectoris, or other ischemic heart 
disease),  prefracture  functional  impairment,  prefracture 
cognitive  decline,  male  sex,  low  Bmi,  and  tachycardia 
(heart rate > 100) on admission. Both loop diuretics and a 
variable containing other diuretics were identified as risk 
factors for mortality using the Cox model, and the variables 
were therefore collapsed in the final model. Use of statins 
demonstrated a statistically significant positive association 
with survival. these eight factors remained statistically sig-
nificant when adjusting for comorbidity diagnosed before 
the fracture like heart failure, hypertension, previous stroke, 
chronic obstructive pulmonary disease (CopD), age, the 
ASA score, nursing home residence, preoperative use of 
medications, laboratory studies on admission, clinical find-
ings on admission, type of fracture, type of surgery, time to 
surgery, time in operation theater, and postoperative com-
plications (CHF, chest infection, and urinary tract infec-
tions). the adjusted Hr for each variable is shown in table 3. 
Forward selection and backward elimination led to the same 
variables being included in the model. No statistically sig-
nificant interactions were observed.
the proportion of deaths among patients using diuretics 
was significantly higher than those among patients not using 
diuretics: 29.4% (32/109) versus 10.6% (27/255) at 6 months, 
36.7% (40/109) versus 16.5% (42/255) at 1 year, and 49.4% 
versus 19.9% at 2 years. the survival of patients using and 
those not using diuretics is shown in Figure 1. Among patients 
using  diuretics  on  admission,  47.7%  used  diuretics  alone; 
38.6% used a beta-blocker, an angiotensin-converting enzyme 
inhibitor (ACei), or an angiotensin ii receptor blocker (ArB), 
and 16.5% used both a beta-blocker and an ACei or ArB. 
19.3% used a statin, and 37.6% used acetylsalicylic acid (as-
pirin). patients using diuretics were more likely to suffer from 
derangements in potassium, urea, and urea/creatinine ratio on 
admission than those not using diuretics (table 4).
patients using statins had increased survival compared 
with those not using statins. they were younger, more likely 
to be living in their own home, and more likely to suffer 
from established CHD than those not using statins. there 
were no differences in ASA score, dependency in ADl, or 
degree of cognitive impairment among patients using and 
those not using statins. 41.4% of the patients with estab-
lished CHD used a statin. Use of statins remained statisti-
cally significantly associated with survival when adjusting 
for potential confounders.
Among patients with established CHD (n = 70), 58.6% 
(n = 41) received treatment with antiplatelet therapy, 44.3% 
(n = 31) received beta-blockers, 35.7% (n = 25) received 
ACei or ArB, 41.4% (n = 29) received statins, and 50.0% 
(n = 35) were treated with diuretics.
table 2.  Univariate Analysis of All Variables and risk of mortality
Unadjusted  
Hazard  
ratio p Value
Background characteristics
  Age at fracture (y) 14.2 <.001
  male sex 6.2 .013
  living in nursing home 37.5 <.001
  iQCoDe score* 38.8 <.001
  Barthel index ≤ 18/20 36.8 <.001
  Body mass index ≤ 20 6.6 .010
  ASA† group iii, iV, or V 34.4 <.001
  History of
    Hypertension 3.9 .049
    Congestive heart failure 11.2 .001
    Coronary heart disease (previous myocardial  
      infarction, angina pectoris, or other ischemic  
      heart disease)
9.7 .002
    previous stroke 2.3 .127
    obstructive pulmonary disease 6.0 .015
  Use of
    Acetylsalicylic acid 1.3 .247
    Beta-blockers 0.4 .538
    Diuretics 31.2 <.001
    Statins 0.5 .045
    Angiotensin-converting enzyme inhibitor or  
      angiotensin antagonist
0.7 .414
preoperative risk factors on admission
  C-reactive protein > 10 mg/l 6.7 .010
  Anemia, hemoglobin <13.4 in male and <11.7  
      in female
8.0 .005
  White blood cells > 10 × 109/l 0.246 .620
  Serum Sodium <137 or >145 mmol/l 1.8 .178
  Serum potassium <3.6 or >5.0 mmol/l 0.1 .820
  Serum Albumin <35 g/l 6.8 .009
  Serum Urea >8 mg/dl 5.3 .022
  Urea/creatinine ratio 7.6 .006
  Atrial fibrillation on admission 4.1 .042
  mean arterial pressure (mmHg) 0.05 .822
  Heart rate > 100 beats per min 4.5 .033
  Body temperature >37.5°C 1.7 .193
  time (h) from admission to surgery 0.3 .866
perioperative and postoperative risk factors
  time (h) in operation theater 1.5 .224
  type of operation—hemiarthroplasty 0.0 .993
  type of anesthesia 3.0 .082
  lowest mean arterial pressure perioperatively  
      (mmHg)
1.9 .166
  received blood transfusion during the stay 2.9 .087
Notes: *the informant Questionnaire on Cognitive Decline in the elderly 
Short Form (17,18).
† American Society of Anesthesiologists (16).JULIEBø ET AL. 446
the most common causes of death after hip fracture were 
cardiovascular diseases (17.2%), fall or accident (15.2%), 
CopD (13.1%), malignancy (12.1%), dementia (11.1%), 
and the hip fracture itself (11.1%). patients using diuretics 
were  more  likely  to  die  from  CopD,  CHD,  and  injury 
caused by falls or accidents than those not using diuretics 
(table 5).
When stratifying for pS quintiles for diuretic therapy in 
the final Cox model, all factors except iQCoDe score re-
mained statistically significantly associated with mortality. 
the adjusted Hr for each variable, both with and without 
adjusting for pS quintiles, is shown in table 3. Sensitivity 
analyses, using both the pS raw score and the stratification 
on quintiles for diuretic therapy and statin therapy, respec-
tively, were performed. the estimated effect of diuretics on 
mortality became stronger when adjusting for pS (unad-
justed Hr = 3.35, confidence interval [Ci] = 1.9–5.6) ver-
sus adjusted for pS raw score (adjusted Hr = 4.2, Ci = 
2.2–7.8) and stratifying for pS quintiles (Hr = 4.0, Ci = 
2.13–7.64). the protective effect of statins became only 
slightly weaker when adjusting for the probability of using 
statins (Hr = 0.22, Ci = 0.08–0.64) versus adjusted for pS 
raw score (Hr = 0.28, Ci = 0.09–0.87) and stratifying for 
pS quintiles (Hr = 0.25, Ci = 0.08–0.79).
Discussion
We have carried out a prospective study evaluating the 
association between mortality after hip fracture and medical 
conditions as well as medications. the proportion dying 
within 6 months was 16.2%; 22.5% were dead after 1 year 
and 28.6% were dead after 2 years of follow-up, and this 
accords well with previous studies on mortality after hip 
fracture (8–10).
Use of diuretics and presence of CHD on admission were 
the two most salient predictors of mortality, also when ad-
justing for potential confounders like CHF and hyperten-
sion and balancing for differences in covariates between the 
diuretic and the no-diuretic groups. Neither beta-blockers 
nor ACei, ArB, or acetylsalicylic acid (aspirin) were asso-
ciated with increased risk of mortality, indicating that the 
diuretics alone may predict mortality in this cohort of el-
derly, frail hip fracture patients. Assuming no hidden bias, 
the survival analysis provides strong evidence (Hr = 4.0,   
p < .001) that treatment with diuretics decreases survival 
time. it is considered unlikely that any set of unknown con-
founders would be so strongly associated with both mortality 
and use of diuretics that they could completely outweigh 
this effect. Diuretics used by those without hypertension or 
CHF have previously been identified as a predictor of 5-year 
mortality in community-dwelling elderly African Americans 
(20),  and  a  large  observational  study  using  pS  methods   
reported chronic diuretic use to be associated with increased 
long-term mortality in patients with chronic heart failure 
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Figure 1.  Comparison of survival patterns in patients using diuretics and 
those not using diuretics.
table 3.  Final Cox proportional Hazards model
Adjusted Hr* 95% Ci p Value Adjusted Hr† 95% Ci p Value
Use of diuretics 3.35 2.06–5.47 <.001 4.03 2.13–7.64 <.001
History of coronary heart disease (previous myocardial infarction, angina  
  pectoris, or other ischemic heart disease)
2.41 1.36–4.24 .002 2.61 1.37–4.98 .004
Barthel index ≤ 18/20 before fracture 2.65 1.37–5.12 .004 2.48 1.23–5.01 .011
Use of statins 0.22 0.08–0.64 .006 0.23 0.08–0.68 .008
male sex 1.98 1.15–3.42 .014 1.53 1.27–4.24 .006
iQCoDe‡ score 1.53 1.04–2.24 .029 1.44 0.95–2.20 .086
Heart rate > 100 beats per min at admittance 2.13 1.05–4.31 .035 2.47 1.18–5.14 .016
Body mass index ≤ 20 1.68 1.01–2.81 .048 1.94 1.13–3.34 .017
Notes: Ci, confidence interval; Hr, hazard ratio.
* Adjusted for variables included in the final model.
† Adjusted for variables included in the final model and stratified by propensity score quintiles.
‡ the informant Questionnaire on Cognitive Decline in the elderly Short Form (17,18). RISK FACTORS OF MORTALITY AFTER HIP FRACTURE 447
(21). No randomized long-term study of the effect of diuret-
ics on mortality in CHF patients has ever been conducted 
(22). moreover, the use of loop diuretics increases urinary 
calcium secretion and has been associated with increased 
risk of hip fracture, increased rate of hipbone loss, and in-
creased risk of implant failure after primary total hip arthro-
plasty (23–25). the medications have not previously been 
assessed as risk factors for mortality in hip fracture patients, 
and the finding needs to be evaluated by others.
29.9% of the patients (n = 109) used diuretics on admis-
sion, whereas 10.7% (n = 39) suffered from CHF. only 
31.2% of the patients using diuretics had an established di-
agnosis of CHF on admission, and 47.7% used diuretics as 
monotherapy. patients using diuretics were more likely to 
suffer from derangement in potassium, increased level of 
urea, and increased urea/creatinine ratio, and they had an 
increased risk of death caused by falls or accidents. more-
over, the risk of death from CopD in patients using diuret-
ics was almost equal to that from CHD. Diuretics cause 
dehydration, and theoretically, they may also enhance a po-
tential hypokalemia caused by the beta2-agonists used in the 
management of CopD. the increased risk of death from 
CopD in patients using diuretics does also illustrate the dif-
ficulties in diagnosing the cause of dyspnea in old frail pa-
tients. our findings are consistent with the hypothesis that 
drugs used for treatment of chronic pulmonary diseases, 
CHD, and CHF may be associated with fatal adverse drug 
events (26,27).
Use of statins was associated with improved survival, in-
dicating a positive effect of the drug and hence supporting 
the hypothesis that statins are effective drugs in preventing 
mortality in elderly cardiovascular patients (28) as well as 
in surgical patients (29). in addition to their effects on lip-
ids, statins have beneficial effects usually described under 
the term pleiotropic. the pleiotropic effects include anti-
inflammatory properties, which may play a role in preven-
tion of cardiovascular events as well as in modifying the 
inflammatory responses caused by the surgery and the hip 
table 4.  Univariate Analysis of the relationship Between patient Characteristics and the Use of Diuretics
Use diuretics,  
n = 109 (29.9%)
No diuretics,  
n = 255 (70.1%) p Value
Cognitive impairment*, n (%) 51† (53.7) 90‡ (38.1) .010
Barthel index ≤ 18/20, n (%) 52§ (57.8) 88‖ (43.6) .025
Age, mean (SD) 85.0 (6.58) 83.0 (6.85) .016
male sex, n (%) 21 (19.3) 67 (26.3) .153
Body mass index ≤ 20, n (%) 64 (27.6) 25 (25.8) .736
Diagnosis on admission, n (%)
  Coronary heart disease¶ 35 (32.1) 35 (13.7) <.001
  Congestive heart failure 34 (31.2) 21 (8.2) <.001
  Hypertension 48 (44.0) 73 (28.6) .004
Atrial fibrillation on admission, n (%) 19# (18.3) 29**(12.2) .124
medications on admission, n (%)
  Acetylsalicylic acid 41 (37.6) 75 (29.4) .124
  Beta-blockers 40 (36.7) 44 (17.3) <.001
  Angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist 35 (32.1) 56 (22.0) .041
  Statins 21 (19.3) 31 (12.2) .076
ASA†† group iii, iV, or V, n (%) 73 (67.0) 108 (42.5) <.001
laboratory findings on admission, n (%)
  Serum Sodium <137 or >145 mmol/l 23 (21.1) 59 (23.1) .670
  Serum potassium <3.6 or >5.0 mmol/l 20 (18.3) 19 (7.5) .002
  Serum Urea >8 mg/dl 69 (63.3) 94 (36.9) <.001
Notes: *the informant Questionnaire on Cognitive Decline in the elderly Short Form (17,18) ≥ 3.6.
† n = 95.
‡ n = 236.
§ n = 90.
‖ n = 202.
¶ previous myocardial infarction, angina pectoris, or ischemia.
# n = 104.
** n = 238.
†† American Society of Anesthesiologists (16).
table 5.  Causes of Death in patients Using Diuretics and in  
those Not Using Diuretics
Causes of Death
patients Using  
Diuretics, n = 50
patients Not Using   
Diuretics, n = 49
malignancy, n (%) 4 (8.0) 8 (16.3)
Dementia, n (%) 5 (10.0) 6 (12.2)
Cardiovascular disease, n (%) 10 (20.0) 7 (14.3)
Stroke, n (%) 2 (4.0) 4 (8.0)
obstructive pulmonary disease, n (%) 9 (18.0) 4 (8.2)
infections, n (%) 4 (7.0) 5 (10.2)
Fall or accident, n (%) 9 (18.0) 6 (12.2)
others, n (%) 4 (7.0) 4 (8.0)
Death related to hip fracture, n (%) 5 (10.0) 6 (12.2)JULIEBø ET AL. 448
fracture itself (29). We identified no differences regarding 
ASA score, cognitive impairment, or dependency in ADl in 
patients using and those not using statins. Statins as second-
ary prevention after myocardial infarction are reported to be 
underused in patients older than 80 years (30), which is con-
sistent  with  our  finding  that  patients  using  statins  were 
younger than those not using statins. the effect of statins 
remained statistically significant also when adjusting for 
potential confounding factors like age, sex, and comorbidity 
and when stratifying for the probability of being treated 
with statins. We suggest therefore that the effect of statins 
on outcome after hip fracture needs to be further explored.
Cardiovascular diseases have previously been shown to 
be the most common comorbid condition in hip fracture pa-
tients (14). our study identifies CHD as an independent risk 
factor of mortality and indicates that management of CHD 
and CHF in hip fracture patients does not accord with cur-
rent guidelines (22,31,32). According to the guidelines of 
the American Cardiology Association, most patients with 
CHF should be treated with a combination of three types of 
drug: a diuretic, an ACei or ArB, and a beta-blocker (22). 
Diuretics alone are unable to maintain the clinical stability 
over a long period of time and should not be used alone as 
treatment of CHF. Secondary prevention in patients with 
established  CHD  includes  treatment  with  beta-blockers, 
ACei or ArB, antiplatelet therapy, and lipid management 
(31,32). Beta-blockers and ACei have been shown to lessen 
the symptoms and improve survival in patients with CHF 
and  CHD.  improving  the  diagnosis  and  management  of 
CHD and CHF might therefore have an impact on survival 
in hip fracture patients.
A Bmi of 20 or less increases the risk of death, as stated 
in previous studies (33), including a recently published study 
identifying underweight patients to be at increased risk of 
developing an adverse cardiac event after hip fracture (34). 
Correspondingly, nutritional intervention has been reported 
to reduce postoperative complications and mortality after 4 
months (35,36). low body weight is associated with mortal-
ity also when adjusting for comorbidity (ASA score) and 
might be an indicator of physical frailty (frailty syndrome). 
Whether active measures to increase the body weight in frail 
elderly patients will improve their physical condition and 
hence improve survival in hip fracture patients remains to be 
investigated. Nutrition in the management of hip fracture 
patients constitutes an interesting area for further research. 
None of the surgery-related risk factors were associated with 
mortality in multivariable analysis.
the strengths of our study are the prospective design, the 
use of an official registry to assess date of death, the fact 
that all the patients were admitted acutely, the extent of risk 
factors evaluated, and the use of standardized validated di-
agnostic instruments for assessment of prefracture cogni-
tive impairment and impairment of activities of daily living. 
the main limitations are the observational design, poten-
tially causing limitations by biases related to unmeasured or 
hidden covariates, the relatively small sample size, the lack 
of evaluation of cardiac function (echocardiography), and 
the fact that 76 potentially eligible patients refused to par-
ticipate in the study, thus possibly causing selection bias. 
moreover, 72 patients did not have close relatives and were 
hence excluded from the Cox proportional hazards model 
due to missing data. the patients and their relatives were 
asked on admission to participate in a study including ex-
tensive cognitive testing. At this time, a majority of the pa-
tients were in pain and/or had received opioids. Frail patients 
and patients fearing the test results might have been more 
likely to decline enrollment.
in conclusion, use of diuretics, history of CHD, low Bmi, 
functional impairment, tachycardia on admission, and male 
sex were found to be risk factors for death during the first 2 
years after a hip fracture. Use of statins, on the other hand, 
was associated with increased survival. our findings need to 
be confirmed by others, and improved diagnosis and man-
agement of CHD and CHF in elderly hip fracture patients 
might constitute avenues for future research. it remains to 
be investigated whether improving medical treatment with 
focus on CHD and congestive heart failure will improve 
survival in hip fracture patients.
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